Shilpa Medicare Limited — Updates, 14-02-2026: General Updates
14-02-2026 | 03:42 pm
14-02-2026 | 03:42 pm
Shilpa Medicare partnered with NXI Therapeutics AG for long-term development and manufacturing of a New Chemical Entity for autoimmune disorders. This third international mandate reinforces its CDMO platform, expanding capabilities in innovative therapies and offering long-term growth potential.
No comments yet. Be the first to comment!
